Abstract:Objective: Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell non-Hodgkin's lymphoma. Invasive DLBCL cells are likely to metastasize into extranodal tissue (e.g., the central nervous system) that is difficult for chemotherapy drugs to penetrate, seriously affecting patient prognosis. The mechanism of DLBCL invasion re-mains unclear. This study investigated the association between invasiveness and platelet endothelial cell adhesion molecule-1 (CD31) in DLBCL. Methods: This study consisted of 40 newly diagnosed DLBCL patients. Differentially expressed genes and pathways in invasive DLBCL cells were identified using real-time polymerase chain reaction, western blotting, immunofluorescence, and immunohistochemical staining, RNA sequencing, and animal experi-ments. The effect of CD31-overexpressing DLBCL cells on the interactions between endothelial cells was deter-mined using scanning electron microscopy. The interactions between CD8+ T cells and DLBCL cells were examined using xenograft models and single-cell RNA sequencing. Results: CD31 was upregulated in patients with multiple metastatic tumor foci compared to patients with a single tumor focus. CD31-overexpressing DLBCL cells formed more metastatic foci in mice and shortened mouse survival time. CD31 disrupted the tight junctions between endo-thelial cells of the blood-brain barrier by activating the osteopontin-epidermal growth factor receptor-tight junction protein 1/tight junction protein-2 axis through the protein kinase B (AKT) pathway, enabling DLBCL to enter the central nervous system to form central nervous system lymphoma. Furthermore, CD31-overexpressing DLBCL cells recruited CD31+ CD8+ T cells that failed to synthesize interferon-? (INF-?), tumor necrosis factor-a (TNF-a), and perforin via the activated mTOR pathway. Some target genes, such as those encoding S100 calcium-binding protein A4, macrophage-activating factor, and class I b-tubulin, may be used to treat this type of DLBCL surrounded by functionally suppressed CD31+ memory T cells. Conclusions: Our study suggests that DLBCL invasion is associated with CD31. The presence of CD31 in DLBCL lesions could represent a valuable target for treating central nervous system lymphoma and restoring CD8+ T-cell function.

Downregulation Of Metadherin Inhibits The Invasiveness Of Diffuse Large B Cell Lymphoma

Silence of MACC1 Decreases Cell Migration and Invasion in Human Malignant Melanoma Through Inhibiting the EMT.

Metadherin Regulates Proliferation and Metastasis Via Actin Cytoskeletal Remodelling in Non-Small Cell Lung Cancer

Metadherin Enhances the Invasiveness of Breast Cancer Cells by Inducing Epithelial to Mesenchymal Transition.

Retraction Note: Downregulation of Long Non-Coding RNA TUG1 Suppresses Tumor Growth by Promoting Ubiquitination of MET in Diffuse Large B-cell Lymphoma

Metadherin Regulates Metastasis of Squamous Cell Carcinoma of the Head and Neck Via Akt Signalling Pathway-Mediated Epithelial-Mesenchymal Transition

Metadherin Mediates Lipopolysaccharide-Induced Migration and Invasion of Breast Cancer Cells

AP2M1 Inhibits Proliferation and Invasion of Diffuse Large B-cell Lymphoma Cells

Metadherin Regulates Actin Cytoskeletal Remodeling and Enhances Human Gastric Cancer Metastasis Via Epithelial-Mesenchymal Transition

Metadherin Promotes the Development of Bladder Cancer by Enhancing Cell Division

MTDH Promotes Metastasis of Clear Cell Renal Cell Carcinoma by Activating SND1-mediated ERK Signaling and Epithelial-Mesenchymal Transition.

Increased Expression Of Metadherin Protein Predicts Worse Disease-Free And Overall Survival In Laryngeal Squamous Cell Carcinoma

Metadherin Regulates Epithelial-Mesenchymal Transition in Carcinoma.

Diffuse Large B-Cell Lymphoma Promotes Endothelial-to-Mesenchymal Transition Via WNT10A/Beta-Catenin/Snail Signaling.

DDHD2 is Involved in the Malignant Progression of Early Luminal A Breast Cancer by Changing Cell Membrane Proteins and Immune Responses Functionality

Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition.

Mta1 Downregulation Inhibits Malignant Potential in A Small Cell Lung Cancer Cell Line

Metadherin: An emerging key regulator of the malignant progression of multiple cancers

JAM-A Overexpression is Related to Disease Progression in Diffuse Large B-cell Lymphoma and Downregulated by Lenalidomide

Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma

CD31 Promotes Diffuse Large B-cell Lymphoma Metastasis by Upregulating OPN Through the AKT Pathway and Inhibiting CD8+ T Cells Through the Mtor Pathway.